Inventor
KREUZBERG MARIA
DE15 patents
⚠️ This page may combine multiple inventors who share the name “KREUZBERG MARIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GANYMED PHARMACEUTICALS AG
6 patentsUS10233253B2Mar 19, 2019
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS AG7 citations83
US10919974B2Feb 16, 2021
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS AG0 citations61
US9932401B2Apr 3, 2018
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG1 citations61
US9902778B2Feb 27, 2018
Cancer therapy using CLDN6 target-directed antibodies in vivo
GANYMED PHARMACEUTICALS AG1 citations61
US10844133B2Nov 24, 2020
Cancer therapy using CLDN6 target-directed antibodies in vivo
GANYMED PHARMACEUTICALS AG0 citations51
US10745477B2Aug 18, 2020
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG0 citations51
SAHIN UGUR
3 patentsBIONTECH AG
3 patentsUS10604568B2Mar 31, 2020
Diagnosis and therapy of cancer involving cancer stem cells
BIONTECH AG6 citations80
US11787862B2Oct 17, 2023
Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases
BIONTECH AG3 citations68
US11795218B2Oct 24, 2023
Diagnosis and therapy of cancer involving cancer stem cells
BIONTECH AG0 citations59
GANYMED PHARMACEUTICALS GMBH
3 patentsUS11859008B2Jan 2, 2024
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS GMBH2 citations71
US11541127B2Jan 3, 2023
Drug conjugates comprising antibodies against claudin 18.2
GANYMED PHARMACEUTICALS GMBH2 citations71
US11858988B2Jan 2, 2024
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS GMBH0 citations61